Immunai

We are proud to expand our partnership with AstraZeneca in a multi-year collaboration aimed at optimizing clinical trials in oncology. By leveraging our AI-powered platforms, we’re working together to enhance clinical decision-making and accelerate drug development in oncology. Building on our shared success since 2022, this collaboration focuses on tackling some of the biggest challenges in clinical trials, like dose selection and patient responses, to bring new therapies to patients faster and more efficiently. Learn more about our new multi-year partnership here: https://lnkd.in/dFKTDczZ

The immune system holds valuable data for advancing medicine. Our collaboration with Teva Pharmaceuticals applies AI and our immune cell atlas to analyze patient responses, optimize dosing, and identify key biomarkers. Together, we’re turning complex data into meaningful progress for new therapies. Thanks to The Cancer Letter for sharing our work!

In drug development, every decision counts. Our partnership with Teva Pharmaceuticals is bringing immune profiling into the earlier stages of development to generate deeper insights into autoimmune diseases and their mechanisms. As highlighted in GenomeWeb by Adam Bonislawski, our CEO, Noam Solomon explains how this collaboration leverages our AMICA™ platform and AI-driven insights to address critical questions like dose optimization, patient selection, and understanding mechanisms of action.

🏆Immunai has been named one of the 25 techbio leaders shaping the AI-biology convergence in 2024 via  @R&D - Research & Development World Coming in hot in the top 10, this recognition highlights the progress we’ve made in combining AI and single-cell genomics to better understand the immune system. Our work with partners like AstraZeneca and Teva Pharmaceuticals reflects our commitment to advancing clinical trials and improving patient outcomes through smarter decision-making. We’re honored to be included alongside other innovators in the field and remain focused on unlocking the immune system’s potential to transform healthcare. Explore the full list, we’re in good company with @Xaira @Recursion Pharmaceuticals, and @PathAI and @AION labs https://lnkd.in/dr5iR7YQ CC: @Brian Buntz  #RD100 #AI #Biotech #TechBio

🧬 This month, as part of our “Inside Immunai” series, we’re thrilled to spotlight Reuven Mizrahi, Immunai’s CPA controller. Reuven is a leader who proves that passion and adaptability can turn challenges into opportunities. Reuven first crossed paths with Immunai while managing its very first audit as part of EY’s high-tech team. From day one, he was struck by our mission to make a positive impact on the world, combined with the complex financial challenges that few startups face.  Shortly after joining Immunai, Reuven embraced a steep learning curve, navigating the complexities of biotech finance as the company’s sole finance professional. With determination and a collaborative spirit, he tackled everything from equity management to audits, all while immersing himself in the dynamic biotech sector. Fast forward to today, Reuven and the finance team (special shoutout to Roy Cohen and Sagi Atia CPA, (MBT)) have transformed Immunai’s finance operations with fresh energy and expertise. From efficiently closing accounting periods to implementing new financial systems, he’s been instrumental in keeping pace with the company’s constant evolution. Whether he’s managing equity, navigating fundraising, or juggling new biotech-specific accounting challenges, Reuven thrives on connecting the dots others might overlook. Thank you for being such an integral part of Immunai’s journey, Rueven! If you’re looking for a place to grow and make an impact, explore opportunities with us here: https://lnkd.in/dri8bPpS #Biotech #MachineLearning #Immunology #Innovation #Healthcare

Immunai has been named Immunology Innovation of the Year by the BioTech Breakthrough Awards! The Biotech Breakthrough Awards celebrate excellence in biotechnology, highlighting companies making substantial advancements in healthcare and scientific innovation. This award reflects our commitment to advancing drug discovery through our platform and the insights we discover. We’re continually working to give pharmaceutical teams a clearer view of immune responses at the single-cell level. What an inspiring group to be a part of—check out the full winners list here: https://lnkd.in/gYXC6PQ5

Streamlining the journey from clinical trials to effective therapies is a mission we share with Teva Pharmaceuticals. Through our new multi-year collaboration, we're leveraging our AI-powered platforms—AMICA™ and the Immunodynamics Engine (IDE)™—to enhance decision-making in immunology and immuno-oncology trials. By focusing on understanding drug mechanisms, optimizing dose selection, and analyzing biomarkers, we're addressing key challenges to accelerate the development process. Learn more about our collaboration with Teva from Roman Kasianov in BioPharmaTrend.com: https://lnkd.in/d-Rcq_tK

Excited to share that Immunai’s AI platform, #AMICA, is nominated for AI Product of the Year at Geektime’s GeekAwards 2024!  Kudos to the Immunai team for pushing the boundaries of drug discovery and development! #GeekAwards2024 #AIInnovation 👉 Vote here and join us at the GeekAwards Summit on December 11th! https://lnkd.in/emRTcYFi

Inside each of our cells lies a unique story of immune response. On the Impact AI Podcast, our CEO @Noam Solomon spoke with Heather Couture, PhD about how our immune atlas leverages single-cell genomics and AI to drive more precise drug discovery. By mapping these cellular narratives, Immunai is charting a path toward therapies that don’t just treat but truly understand the patient. Listen to the full episode here: https://lnkd.in/dud9_RcM

🧬This month, we’re featuring David Brocks, as the second team member in our Inside Immunai spotlight series. David has been with us for over four years, now working as Director of Computational Biology. His journey at the company began thanks to a recommendation from his close friend, the late Elad Chomsky, who embodied our empathetic culture and the brilliant people who work here. Today, David is driven by those rare "eureka" moments that come from pushing boundaries in tech, and at Immunai, he leads the team responsible for building what he calls the "ChatGPT of the immune system." What keeps David going? Immunai’s self-optimizing culture. In his words, there hasn't been a year that hasn't been better than the one before. It’s the combination of our mission, the people, and the sense of appreciation that makes Immunai a special place to be. We love having you on our team, David! Fun fact: David enjoys playing ‘Soulsborne’ video games—drop a comment if you’re a gamer too! 🎮 You can join David, explore opportunities with Immunai here: https://lnkd.in/dri8bPpS #Biotech #MachineLearning #Immunology #Innovation #Healthcare